Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T11970 |
MCL-1/BCL-2-IN-3
|
Others | Others |
MCL-1/BCL-2-IN-3 is a selective and potent Mcl-1 and Bcl-2 dual inhibitor with IC50s of 5.95 and 4.78 μM, respectiely. | |||
T16029 |
Mcl1-IN-3
|
Others | Others |
Mcl1-IN-3 is an Mcl1 inhibitor. It has an IC50 and Ki of 0.67 and 0.13 μM, respectively. | |||
T62941 | Bcl-2/Mcl-1-IN-3 | ||
Bcl-2/Mcl-1-IN-3 是一种 Bcl-2/Mcl-1 抑制剂,作用于 Mcl-1 (Ki: 0.14 μM) 和 Bcl-2 (Ki: 0.23 μM),能够用于研究癌症。 | |||
T11972 |
Mcl-1 inhibitor 3
|
BCL | Apoptosis |
Mcl-1 inhibitor 3 shows good pharmacokinetic properties and excellent in vivo efficacy without toxicity.Mcl-1 inhibitor 3 is a highly potent and orally activate macrocyclic Mcl-1 inhibitor (Ki= 0.061 nM; IC50=19 nM in an OPM-2 cell viability assay). | |||
T35481 |
DD 03-171
|
||
Potent and selective BTK Degrader (IC50 = 5.1 nM); degrades BTK in a proteasome- and CRBN-dependent manner. Suppresses BTK signaling and proliferation in mantle cell lymphoma (MCL) cells by degrading BTK, IKFZ1, and IKFZ3 (3 validated targets in B-cell malignancies). Also degrades Ibrutinib (Cat. No. 6813) -resistant C481S-BTK mutant cancer cells. Exhibits no binding against a panel of 468 kinases at 1 μM. Reduces tumor burden and extends survival in lymphoma patient-derived xenograft models. | |||
T29060 |
UNBS-1450
UNBS 1450,UBS1450,UBS-1450,UBS 1450 |
||
UNBS-1450 is a sodium channel antagonist. UNBS-1450 is a hemi-synthetic cardenolide derived from 2″-oxovorusharin, it is effective against various cancer cell types with an excellent differential toxicity. At low nanomolar concentrations, UNBS-1450 induce |